A review of the virological efficacy of the 4 world health organization-recommended tenofovir-containing regimens for initial HIV therapy

Clinical Infectious Diseases

Volumn 54, Issue 6, 2012, Pages 862-875

  Tang, Michele W ^a   Kanki, Phyllis J ^b   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

DRUG EFFICACY; DRUG HALF LIFE; EARLY TERMINATION OF CLINICAL TRIAL; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

ADENINE; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; NEVIRAPINE; PHOSPHONIC ACIDS; TREATMENT FAILURE; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84857563447     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1034     Document Type: Review

References (49)

1. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17: 1151-6. (Pubitemid 36667757)
2. Scarsi K, Darin K, Rawizza D, et al. TDF-3TC-NVP is inferior to AZT- 3TC-NVP in a large ART program in Nigeria [abstract]. In: The 10th International AIDS Conference. Vienna: International AIDS Society, 2010.
3. Darin K, Scarsi K, Meloni S, Rawizza H, Kanki P. Clinical and virologic outcomes of six first-line regimens in a large ART program in Nigeria. In: The 10th International AIDS Conference. Vienna: International AIDS Society, 2010.
4. Landman R, Koulla-Shiro S, Sow PS, et al. Evaluation of four tenofovircontaining regimens as first-line treatments in Cameroon and Senegal: the DAYANA Trial, IMEA032/ANRS12115. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: International AIDS Society, 2011.
5. Stephan C, Tutschkus M, Khaykin P, et al. Clinical and lipometabolic outcome of nevirapine- vs efavirenz-initial antiretroviral therapy, both with TDF/FTC-backbone. In: 12th European AIDS Conference. Cologne, Germany: European AIDS Clinical Society, 2009.
6. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 380-8.
7. Towner W, Kerrigan H, LaRiviere M, et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: a pilot study. Int Cong Drug Therapy HIV 2004.
8. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008; 46: 1127-9. (Pubitemid 351589888)
9. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ ritonavir, each combined with tenofovir disoproxil fumarate/ emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011; 16: 339-48.
10. Dejesus E, Mills A, Bhatti L, Conner C, Storfer S. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients. Int J Clin Pract 2011; 65: 1240-9.
11. Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediaterelease twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther 2011; 16: 759-69.
12. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363: 1499-509.
13. Vallecillo G, Domingo P, Mallolas J, et al. Evaluation of the safety and effectiveness of nevirapine plus coformulated Tenofovir/Emtricitabine as first-line therapy in routine clinical practice. AIDS Res Hum Retroviruses 2011.
14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201. (Pubitemid 38917996)
15. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125-33. (Pubitemid 47482607)
16. Maggiolo F, Ripamonti D,Migliorino G, et al. Comparison of three oncea- day regimens as first-line HAART [Abstract THPE0103]. In: XVI International AIDS Conference.Toronto: International AIDS Society 2006.
17. Keiser P, Nassar N, Armas L, Sanchez J, Sandoval J, Moreno S. An observational cohort comparison of zidovudine-lamivudine-efavirenz vs. tenofovir-lamivudine-efavirenz in anti-retroviral naive patients in a large urban clinic [abstract WePe12.2C20]. In: The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro: International AIDS Society, 2005.
18. Torti CD, Quiros-Roldan E, Cologni G, et al. Tenofovir1lamivudine1 efavirenz versus zidovudine1lamivudine1lopinavir/ritonavir in antiretroviral naive HIV-infected patients: interim results of a prospective randomized study (SISTHER) of the Italian MASTER Cohort. In: 10th European AIDS Conference. Dublin, Ireland, 2005: 17-20.
19. DeJesus E, Saple D, Morales-Ramirez J, et al. Elvucitabine phase II 48 Week interim results Show safety and efficacy Profiles similar to lamivudine in treatment naive HIV-1 infected patients with a Unique pharmacokinetic Profile [abstract H-892]. In: 48th International con- ference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2008.
20. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60. (Pubitemid 43113030)
21. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, doubleblind randomised controlled trial. Lancet 2009; 374: 796-806.
22. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
23. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55: 49-57.
24. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatmentnaive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51: 855-64.
25. Campbell T, Smeaton L, Kumarasamy N, et al. Efficacy and safety of EFV with either co-formulated 3TC/ZDV or FTC/TDF for initial treatment of HIV-1-infected men and women in diverse multinational settings: ACTG PEARLS Study [abstract 149LB]. In: 18th conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: Foundation for Retrovirology and Human Health, 2011.
26. Miro JM, Manzardo C, Ferrer E, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-infected patients taking antiretroviral regimens based on efavirenz, lopinavir-ritonavir, and atazanavir-ritonavir: 48-week results of a randomized controlled trial (the Advanz-3 trial). In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: International AIDS Society, 2011.
27. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind activecontrolled trial. Lancet 2011; 378: 238-46.
28. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25: F7-12.
29. Vernazza P, Wang C, Pozniak A, et al. Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naïve HIV-1- infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study A5271015). In: 6th IAS Conference on HIV Pathogenesis Treatment, Prevention. Rome, Italy: International AIDS Society, 2011.
30. Bowman V, Rieg G, Jain S, et al. 48 Week results of a pilot randomized study of a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen of raltegravir (RAL) 1 lopinavir/ritonavir (LPV/r) versus efavirenz/tenofovir disoproxil fumarate/ emtricitabine (EFV/TDF/FTC) in antiretroviral-naive patients: CCTG 589. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: International AIDS Society, 2011.
31. Gay CL, Mayo AJ, Mfalila CK, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS 2011; 25: 941-9.
32. Landman R, Poupard M, Diallo M, et al. Tenofovir-emtricitabineefavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 2009; 8: 379-84.
33. Das S, Arumainayagam J, Kumari B, Chandramani S, Riddell L, Ghanem M. The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients. J Int AIDS Soc 2008; 11(Suppl 1): P15.
34. Malhotra S, Kao A, Liu A, Estes R, Pitrak D. Benefits of HAART in a minority, urban clinic compared to a published randomized, controlled trial. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney: International AIDS Society, 2007.
35. Perez-Valero I, Martin N, Valiente B, et al. Naive patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill. J Int AIDS Soc 2010; 13(Suppl 4): P122.
36. Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res 2008; 134: 147-56.
37. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63. (Pubitemid 38496486)
38. van den Berg-Wolf M, Hullsiek KH, Peng G, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 2008; 9: 324-36.
39. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapinebased initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22: 2117-25.
40. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002; 3: 296-303. (Pubitemid 34830680)
41. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. AIDS 2002; 16: 53-61. (Pubitemid 34062182)
42. Cooper CL, van Heeswijk RP. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med 2007; 8: 1-7. (Pubitemid 46117834)
43. Macgregor TR. ''Forgiving'' a missed daily dose. AIDS Res Hum Retroviruses 2011; 27: 345-6.
44. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antivir Ther 2001; 6: 83-8. (Pubitemid 32652092)
45. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48: 176-82. (Pubitemid 38040195)
46. Wang LH, Begley J, St Claire RL 3rd, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20: 1173-82. (Pubitemid 39557868)
47. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921-30. (Pubitemid 41681890)
48. Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6: 291-301. (Pubitemid 43336963)
49. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 409-17.